CALIBRATE
Research type
Research Study
Full title
CAmbridge LIquid Biopsy and tumouR profiling study for pATients on Early phase clinical trials
IRAS ID
138069
Contact name
Richard Baird
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Why? Some patients respond to anti-cancer drugs whilst others do not, despite having tumours with, apparently, similar characteristics such as site of origin. This variability in response can in some cases be explained by the genetic profile of the tumour. Therefore studying the relationship between the molecular profiles of individual cancers and the response to therapy over time is of crucial importance in drug development. However this endeavour is hampered by the difficulty in accessing suitable tumour material for analysis. Many patients’ tumours are at anatomical sites which make biopsy difficult / hazardous which is in addition to the discomfort of a biopsy procedure.
What? This study will explore the potential of the circulating tumour DNA as predictive factor of response/resistance to anticancer treatment.
Who? All the patients treated on an early phase trial in Addenbrooke’s Hospital will be eligible for this study.
Where? This study will be conducted within the early phase clinical trials department of Addenbrooke´s Hospital (Cambridge).
How? The project will involve the collection and study of the archived tumour tissue (mandatory), serial blood samples (mandatory) and fresh tumour biopsies (optional).
REC name
South Central - Hampshire A Research Ethics Committee
REC reference
14/SC/1170
Date of REC Opinion
22 Oct 2014
REC opinion
Further Information Favourable Opinion